Pfizer to Acquire Anacor

Strong fit with Pfizer’s Inflammation and Immunology portfolio
Expected to enhance near-term revenue growth for the innovative business
Anacor’s flagship asset, crisaborole, has a New Drug Application under review by the U.S. Food and Drug Administration (FDA), is a differentiated non-steroidal topical PDE4 inhibitor with compelling clinical data, and if approved, has the potential to be an important first-line treatment option for patients with atopic dermatitis
 
NEW YORK & PALO ALTO, Calif.-- Pfizer Inc. (PFE) and Anacor Pharmaceuticals, Inc. (ANAC) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Anacor for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes. The Boards of Directors of both companies have unanimously approved the transaction. Anacor’s flagship asset, crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, is currently under review by the U.S. FDA for the treatment of mild-to-moderate atopic dermatitis, commonly referred to as eczema.
Read more: Anacor Pharmaceuticals Inc ( ANAC )

Oramed Patent Being Granted in China for Oral Administration of Proteins

JERUSALEM, May 11, 2016 -- Oramed Pharmaceuticals Inc. (ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that an official Notification of Granting Patent Right was issued for the Company's patent for its invention titled "Methods and Compositions for Oral Administrations of Proteins" by the State Intellectual Property Office of the People's Republic of China.
 
About Oramed Pharmaceuticals 
 
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
Read more: Oramed Pharmaceuticals Inc ( ORMP )

Eagle Pharmaceuticals, Inc. Reports First Quarter 2016 Results; Bendeka Achieves 71% Total Market Share

-- Bendeka leads with approximately 77% market share among hospital outpatients and clinics --
 
WOODCLIFF LAKE, N.J.-- Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (EGRX) today announced its financial results for the first quarter ended March 31, 2016. Highlights of and subsequent to the first quarter of 2016 include:
 
Business Highlights:
 
Bendeka® was launched January 28, 2016 by Eagle’s marketing partner, Teva Pharmaceutical Industries (Teva); total market share, as of May 6, 2016, was 71% and 77% in core hospital outpatient and clinic segments combined (representing 70% of the total market);
Read more: Eagle Pharmaceuticals Inc ( EGRX )

Horizon Pharma plc Announces First-Quarter 2016 Financial Results

First-Quarter 2016 Net Sales of $204.7 Million, Up 81 Percent; First-Quarter 2016 Adjusted Operating Cash Flow of $67.9 Million; GAAP Operating Cash Flow of $54.2 Million; Confirms Full-Year 2016 Net Sales Guidance of $1.025 to $1.050 Billion and Full-Year 2016 Adjusted EBITDA Guidance of $505 to $520 Million; Completes Enrollment of ACTIMMUNE Phase 3 Clinical Trial in Friedreich's Ataxia; Board of Directors Authorizes Share Repurchase Program
DUBLIN, IRELAND--(Marketwired - May 9, 2016) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its first-quarter 2016 financial results today and confirmed its full-year 2016 net sales and adjusted EBITDA guidance.
Read more: Horizon Pharma plc ( HZNP )

Cardiome and Allergan Announce XYDALBA™ (Dalbavancin) Licensing Agreement in International Markets

VANCOUVER, May 5, 2016  Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced that its affiliate has signed an exclusive license agreement with an affiliate of Allergan plc that will result in the Cardiome Group ("Cardiome") commercializing XYDALBA™ (Dalbavancin) in France, the U.K., Germany, Belgium, Nordic nations, certain other European nations (not already partnered), various Middle Eastern nations and Canada. Cardiome will provide Allergan with a staggered upfront payment totalling US$13 million and will provide Allergan additional milestone payments and royalties based upon commercial achievements and sales of XYDALBA™. Additional terms of the agreement were not disclosed.
XYDALBA™ was approved by the European Medicines Agency (EMA) in February 2015 as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in adults and by the U.S. Food and Drug Administration (FDA) in May 2014 for the treatment of adult patients with ABSSSI caused by susceptible Gram-positive bacteria, including MRSA. Dalbavancin is commercialized under the trade name DALVANCE® in the U.S. and XYDALBA™ in certain countries outside the U.S.
Read more: Cardiome Pharma Corp ( CRME / COM )

Videos / Webinars

View all videos